Antithrombotic Management of Acute Mesenteric Ischaemia

NCT05706012 | Completed

• 1 other identifier: s67503
• Study Type: observational
• Target: 51
• Locations: 1 country
• Sites: 1

Brief Summary

Guidelines on the acute and long-term pharmacological treatment of acute mesenteric ischaemia (AMI) recommend the use of thrombolytic, antiplatelet or anticoagulant therapy depending on the aetiology of AMI and the use of stenting but only few details are given on the choice of the drug, dose and duration of treatment. Besides, recommendations are mainly based on data on coronary, cerebral and other peripheral artery diseases and do also not take into account the altered drug absorption in patients with short bowel syndrome, in which AMI can result.This case-based survey will inform us on the current international clinical practice of long-term antithrombotic management of AMI.

Conditions

Acute Mesenteric Ischemia; Short Bowel Syndrome

Outcome Measures

Primary Outcomes (1)

• Type of antithrombotic therapy

  Overview of the type of long-term antithrombotic therapy that is prescribed in SBS patients with AMI, depending on the anatomy of the gastrointestinal tract, the aetiology of AMI and whether or not revascularisation of the occluding blood vessel has been performed

  April 2023

Secondary Outcomes (3)

• Duration of antithrombotic therapy

  April 2023

• Initial dose of antithrombotic therapy

  April 2023

• Dose adjustments of antithrombotic therapy

  April 2023

Study Arms (1)

Gastro-enterologists and anticoagulation specialists

An online survey will be sent to question current clinical practice in long-term antithrombotic management of AMI in SBS patients.

Other: Survey

Interventions

Survey OTHER

Online survey questioning the current clinical practice on long-term antithrombotic management of AMI in SBS patients

Gastro-enterologists and anticoagulation specialists

Eligibility Criteria

• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

international gastro-enterologists an cardiologists

You may qualify if:

• gastro-enterologist or cardiologist with expertise in treating SBS patients resulting from AMI

You may not qualify if:

• none

Sponsors & Collaborators

• Universitaire Ziekenhuizen KU Leuven: lead

Study Sites (1)

University Hospitals Leuven

Leuven, 3000, Belgium

Location

MeSH Terms

Conditions

Short Bowel Syndrome

Interventions

Surveys and Questionnaires

Condition Hierarchy (Ancestors)

Malabsorption Syndromes; Intestinal Diseases; Gastrointestinal Diseases; Digestive System Diseases; Postoperative Complications; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Data Collection; Epidemiologic Methods; Investigative Techniques; Health Care Evaluation Mechanisms; Quality of Health Care; Health Care Quality, Access, and Evaluation; Public Health; Environment and Public Health

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 20, 2023
• First Posted: January 31, 2023
• Study Start: June 30, 2023
• Primary Completion: February 29, 2024
• Study Completion: February 29, 2024
• Last Updated: May 9, 2024

Record last verified: 2023-11

Data Sharing

• IPD Sharing: Will not share

Locations

BE (1)